Caster Semenya, athlete classification, and fair equality of opportunity in sport.

applied and professional ethics distributive justice sexuality/gender

Journal

Journal of medical ethics
ISSN: 1473-4257
Titre abrégé: J Med Ethics
Pays: England
ID NLM: 7513619

Informations de publication

Date de publication:
09 2020
Historique:
received: 04 11 2019
revised: 18 02 2020
accepted: 03 03 2020
pubmed: 22 7 2020
medline: 18 9 2021
entrez: 22 7 2020
Statut: ppublish

Résumé

According to the Differences of Sex Development (DSD) Regulations of the International Association of Athletics Federations (IAAF), Caster Semenya and other athletes with heightened testosterone levels are considered non-eligible for middle distance running races in the women's class. Based on an analysis of fair equality of opportunity in sport, I take a critical look at the Semenya case and at IAAF's DSD Regulations. I distinguish between what I call stable and dynamic inequalities between athletes. Stable inequalities are those that athletes cannot impact or control in any significant way such as inequalities in biological sex, body size and chronological age. Dynamic inequalities, such as inequalities in strength, speed and endurance, or in technical and tactical skills, can be impacted and to a certain extent controlled by athletes. If stable inequalities exert significant and systematic impact on performance, they provide a rationale for classification. If high testosterone level is an inborn, strong and systemic driver of performance development, inequalities in such levels can provide a rationale for classification. As is emphasised by the Court of Arbitration for Sport (CAS), this leads to a dilemma of rights: the right of Semenya to compete in sport according to her legal sex and gender identity, and the right of other athletes within the average female testosterone range to compete under fair conditions. I conclude with providing conditional support of the CAS decision in the Semenya case and of IAAF's DSD Regulations.

Identifiants

pubmed: 32690761
pii: medethics-2019-105937
doi: 10.1136/medethics-2019-105937
doi:

Substances chimiques

Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

584-590

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Sigmund Loland (S)

Department of Sport and Social Sciences, The Norwegian School of Sport Sciences, Oslo, Norway sigmund.loland@nih.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH